KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to $966.4 million.

  • Alnylam Pharmaceuticals' Cash & Equivalents rose 35.49% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 35.49%. This contributed to the annual value of $966.4 million for FY2024, which is 18.60% up from last year.
  • Alnylam Pharmaceuticals' Cash & Equivalents amounted to $966.4 million in FY2024, which was up 18.60% from $814.9 million recorded in FY2023.
  • In the past 5 years, Alnylam Pharmaceuticals' Cash & Equivalents registered a high of $966.4 million during FY2024, and its lowest value of $499.0 million during FY2020.
  • Moreover, its 3-year median value for Cash & Equivalents was $866.4 million (2022), whereas its average is $882.6 million.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Cash & Equivalents fell by 9.20% in 2020 and then surged by 64.74% in 2021.
  • Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Cash & Equivalents stood at $499.0 million in 2020, then skyrocketed by 64.74% to $822.2 million in 2021, then increased by 5.38% to $866.4 million in 2022, then decreased by 5.95% to $814.9 million in 2023, then increased by 18.60% to $966.4 million in 2024.